Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, Inc. relating to the parties’ 2019 Collaboration and License Agreement. The company reported that the Tribunal declared that PM647, which is the company’s investigational Prime Editing drug for Alpha-1 Antitrypsin Deficiency (AATD), is within its “Field” as defined by the Agreement, and that Prime Medicine, Inc. (NASDAQ:PRME) therefore did not breach the Agreement and does not owe monetary damages to Beam Therapeutics.

It further clarified that PM647 leverages Prime Medicine’s (NASDAQ:PRME) universal liver lipid nanoparticle to correct the E342K (Pi*Z) mutation in the SERPINA1 gene, which is the most prevalent disease-causing mutation in AATD. Treatment with PM647 in fully humanized mouse models attained high levels of editing efficiency and restored the corrected protein isoform (M-AAT) into the healthy human range at clinically relevant doses.

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company involved in the development of one-time curative genetic therapies.

While we acknowledge the risk and potential of PRME as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRME and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1